Losses
-€40,679 in two years
The 2024 and 2025 financial years closed with a loss. 2025 was the heaviest.
FRAPEJA PHARMA
Lifetime
11 annual accounts with figures on one time axispeak €195,066 (2023)
€53,628▼ 34.3%
lowest -€256,121 (2019)
-€37,162▼ €33,645
peak €176,651 (2023)
€135,972▼ 21.5%
€636,974▲ 1.3%
peak 1.9 FTE (2019)
0 FTE
Board3 names since 2014
1 director
Owners
50%
Documentsfilings and deeds
05-06-202656 days before the deadline
2025abbreviated format
Gross margin from €81,631 to €53,628Loss of €37,162Equity from €173,134 to €135,972
Key points
from the 2025 annual accountsTurnover
≈ €260,000 estimated
The abbreviated format states no turnover.
Debts
€636,974 82% of the balance sheet
Financial debts 35%Suppliers 34%Taxes and wages 0%Other 31%
€146,200 of the debts are secured on the company's own assets. In 2021 that was €323,013.
Liquidity
1.86 was 2.60 in 2024
Short-term debts rose from €182,561 to €261,935.
Filings
11 annual accounts since 2015
Two of the last ten came late. The 2021 accounts came latest: 37 days after the end of the period.
Position in the sector
-€37,162
Lower net result than 87% of companies in retail trade. Sector median €38,016 · 13,231 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 1,423 companies had the same profile as FRAPEJA PHARMA has now. Each dot stands for 4 companies, two years later.
96.5%
were still trading
2.2%
stopped another way
1.0%
went bankrupt
Another 0.4% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,423 companies, not a prediction for FRAPEJA PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, , since 29-03-2024
- 50%score equity €54,724 (2025) · 2025 annual accounts of
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0562774303
1 director appointed, 1 resignation
Resignation: · Appointment: · Permanent representative: · General meeting of 23-09-2024 · Gazette deed
Registered office moved from Lievegem to Ghent
New registered office: Meulesteedsesteenweg 7, 9000 Gent · Previous registered office: Pastoor Moernautstraat 20, 9921 Lievegem · Board meeting of 01-10-2023 · Gazette deed
Capital contribution of €375,000
Contribution: · 37,500 new shares · General meeting of 14-10-2020 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| FRAPEJA PHARMA Ghent | €772,946 | €53,628 | 17.6% | 0 |
| Pharmaconsult Beringen | €669,769 | €75,930 | 42.8% | 0 |
| Apotheek De Wachter Lede | €694,615 | €107,612 | 69.8% | 0 |
| Pharmacie de Walhain Walhain | €944,332 | €76,076 | 58.0% | 0 |
| Apotheek Terkoest Alken | €868,114 | €72,063 | 40.5% | 0 |
| Pharmacie GHUYSEN Blegny | €446,214 | €78,538 | 53.5% | 0.2 |
| APOTHEEK OPLINTER Tienen | €441,025 | €81,205 | 55.3% | 0.1 |
These companies have the same main activity as FRAPEJA PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €441,000 and €944,000, founded between 2003 and 2014.
Official details
Source: KBO- Status
- Active since 18-09-2014Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Establishment units
- 2.273.833.5179000 Ghent, since 01-03-2018
- 2.371.184.2029000 Ghent, since 18-06-2019
- Financial year end
- 31 December
- Peppol
- Reachable since 12-08-2025
Annual accounts 2025
- €772,946▼ 3.6%
- Filing
- Filed on 05-06-2026, 56 days before the end of the filing period
Insights on FRAPEJA PHARMA
FRAPEJA PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from -€24,780 in 2015 to €53,628 in 2025.
The balance sheet grew most in 2019 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about FRAPEJA PHARMA
- What is the company number of FRAPEJA PHARMA?
- The company number of FRAPEJA PHARMA is 0562.774.303. The VAT number is the same number with BE in front: BE 0562.774.303.
- Where is FRAPEJA PHARMA based?
- The registered office is at Meulesteedsesteenweg 7, 9000 Ghent.Company details
- What does FRAPEJA PHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of FRAPEJA PHARMA?
- FRAPEJA PHARMA is a private limited company (BV).
- When was FRAPEJA PHARMA founded?
- FRAPEJA PHARMA was founded on 18-09-2014.
- Is FRAPEJA PHARMA still active?
- Yes, FRAPEJA PHARMA is an active enterprise in the KBO register.
- How many employees does FRAPEJA PHARMA have?
- FRAPEJA PHARMA had an average of 1.9 full-time equivalents in financial year 2019, according to the filed annual accounts.Financials
- What is the turnover of FRAPEJA PHARMA?
- The turnover in financial year 2025 is ≈ €260,000. This figure is estimated from the gross margin of €53,628 and 74 comparable companies (NACE 477). It probably lies between €130,000 and €380,000.
- Is FRAPEJA PHARMA profitable?
- In financial year 2025, FRAPEJA PHARMA made a loss of €37,162.
- Where can I find the annual accounts of FRAPEJA PHARMA?
- FRAPEJA PHARMA filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of FRAPEJA PHARMA due?
- FRAPEJA PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.